ORION NUTRACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4 CAD | -.--% |
|
-.--% | -.--% |
| Apr. 19 | Orion Nutraceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024 | CI |
| Mar. 13 | Joel Dumaresq Resigns as Director of Orion Nutraceuticals Inc | CI |
Valuation
| Fiscal Period: May | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 7.753 | 2.218 | 11.72 | 11.72 | 11.72 |
| Enterprise Value (EV) 1 | 7.748 | 1.76 | 11.49 | 11.76 | 11.81 |
| P/E ratio | -1.09 x | -1.64 x | -12.1 x | -4.47 x | -41.9 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / FCF | -15,922,564 x | 132,030,148 x | -4,118,139 x | 5,548,210 x | 191,984,247 x |
| FCF Yield | -0% | 0% | -0% | 0% | 0% |
| Price to Book | -20.2 x | -8.4 x | 5.92 x | -18.5 x | -12.8 x |
| Nbr of stocks (in thousands) | 1,938 | 6,721 | 29,308 | 29,308 | 29,308 |
| Reference price 2 | 4.000 | 0.3300 | 0.4000 | 0.4000 | 0.4000 |
| Announcement Date | 12/4/19 | 9/28/20 | 9/30/21 | 9/29/22 | 9/28/23 |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: May | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -0.2443 | -2.756 | -0.5149 | -0.535 | -0.3681 | -0.2663 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -0.3528 | -6.391 | -0.3862 | -0.8829 | -2.62 | -0.2797 |
| Net income 1 | -0.3528 | -6.391 | -0.3853 | -0.8829 | -2.62 | -0.2797 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.7754 | -3.667 | -0.2016 | -0.0331 | -0.0894 | -0.009543 |
| Free Cash Flow | - | -0.4866 | 0.0133 | -2.789 | 2.119 | 0.0615 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/21/18 | 12/4/19 | 9/28/20 | 9/30/21 | 9/29/22 | 9/28/23 |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: May | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.03 | 0.09 |
| Net Cash position 1 | 0.35 | 0.01 | 0.46 | 0.24 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | -0.49 | 0.01 | -2.79 | 2.12 | 0.06 |
| ROE (net income / shareholders' equity) | - | -1,600% | 119% | -103% | -390% | 36.1% |
| ROA (Net income/ Total Assets) | - | -253% | -95.8% | -22.2% | -18.9% | -2,480% |
| Assets 1 | - | 2.523 | 0.4021 | 3.979 | 13.88 | 0.0113 |
| Book Value Per Share 2 | 1.150 | -0.2000 | -0.0400 | 0.0700 | -0.0200 | -0.0300 |
| Cash Flow per Share 2 | 0.3400 | 0 | 0.0700 | 0.0100 | 0 | 0 |
| Capex | - | 0.01 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 8/21/18 | 12/4/19 | 9/28/20 | 9/30/21 | 9/29/22 | 9/28/23 |
1CAD in Million2CAD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 8.68M | |
| +39.33% | 6.01B | |
| -18.38% | 4.4B | |
| -9.17% | 3.17B | |
| +3.98% | 3.07B | |
| -3.41% | 2.51B | |
| +48.74% | 1.88B | |
| -4.82% | 1.73B | |
| -1.24% | 1.65B | |
| -8.96% | 1.58B |
- Stock Market
- Equities
- ORI Stock
- Financials Orion Nutraceuticals Inc.
